Navigation Links
Medifast Offers 5 Heart Healthy Tips in Recognition of Friday's National Wear Red Day
Date:1/31/2008

Company showing support for fight against heart disease, the nations #1

killer of women

OWINGS MILLS, Md., Jan. 31 /PRNewswire-FirstCall/ -- In recognition of National Wear Red Day, Medifast, Inc. (NYSE: MED) is offering 5 heart healthy tips to help Americans fight heart disease, the #1 killer among women in the country. National Wear Red Day is Friday, February 1, when Americans nationwide will take women's health to heart by wearing red to show their support for women's heart disease awareness.

Everyone has women in their life, whether it's your wife, mother, girlfriend or sister, but not everyone knows that heart disease in the number one killer of women in America. Heart disease is killing women at an alarming rate, with 1-in-3 American women dying from the disease.

"As a nation we put a lot of effort and money into how we treat heart disease after it happens, but we don't put enough effort into fending off the initial warning signs," said Lisa M. Davis, Ph.D., PA-C, C.N.S., L.D.N., Director of Research and Development, Medifast, Inc. and co-author of the book, 'Anti-Inflammatory Foods for Health' (Fair Winds Press 2008). "A weight loss of 5-10% can greatly reduce the risk of cardiovascular disease, so a lot of these problems can be solved by following a healthier diet and an overall healthier lifestyle."

In support of National Wear Red Day on Friday, February 1st, Medifast is offering the following 5 heart healthy tips:

-- Incorporate soy protein into your diet:

The FDA approved heart healthy claim arose from 27 studies

demonstrating soy protein lowers levels of total cholesterol and

low-density lipoprotein (LDL, or "bad" cholesterol). <
'/>"/>

SOURCE Medifast
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Medifast Announces Winners of Mother-Daughter Challenge
2. Medifast, Inc. Announces Support for Microsoft HealthVault
3. Medifast Announces Updated Full Year 2007 Guidance
4. Medifast Announces Third-Quarter 2007 Results
5. Medifast, Inc. Receives Approval to Sell Medifast Weight Control Centers Franchises in Seven Additional States
6. Medifast, Inc. to Unveil New Advertising Campaign Featuring Genie Francis and New Web Features in Early 2008
7. Medifast, Inc. Director of Research & Development Co-Authors Health Book
8. Medifast Receives Notice Regarding NYSE Listing
9. Medifast Offers Stranded Pure Weight Loss Clients Unique Options
10. Health care incentive model offers collaborative approach
11. Eye-staining technique offers early detection for dry eye syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)... Reawakening a dormant gene could ease sic... (Vocus) December 4, 2008 -- Researchers ...tal.org ) and Dana-Farber Cancer Institute have id... form of hemoglobin normally made only before birt...sform sickle-cell disease and beta-thalassemia -- ...
(Date:12/4/2008)...4 Dr. Stephen Joffe, Craig Joffe, ... Schedule 13D with the U.S.,Securities and Exchan...disclosing ownership of 11.4% of LCA-Vision, Inc. ...xed-site laser vision correction centers in 33 sta...er and former Chairman and CEO of,LCAV. Craig Jo...
(Date:12/4/2008)...Is Mercury a Common Factor?" , , WASHINGTON...s announced last week call into question the safet...s old policy of routinely administering multiple v...sease in Autism Spectrum Disorder Patients, publi...he Cleveland Clinic, Johns Hopkins Kennedy Krieger...
(Date:12/4/2008)...derate-intensity activity or 75 minutes of vigorou...HealthDay News) -- An estimated 65 percent of peop...sical Activity Guidelines for Americans. And 49 pe...physical activity objectives, according to a feder...e 2008 guidelines, released in October by the U.S....
Breaking Medicine News(10 mins):Health News:Turning back the Clock in Inherited Anemias 2Health News:Turning back the Clock in Inherited Anemias 3Health News:Turning back the Clock in Inherited Anemias 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 5Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 6Health News:Researchers & Department of Defense Question Multiple Vaccine Administration 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 3
...ent study researchers say that a diet rich in calc...cheese, yogurt and fortified orange juice can actu... Syndrome (PMS) symptoms. Studies in the past have...e with PMS, however more recent studies suggest th...
...going to the dentists, but did you know that //whe...ou feel scared about dental appointments? A new st...mphasize that although women are 2.5 times as like...than men, men too are as likely to eel afraid, onl...
...to find out why the diabetes drug thiazolidinedion...niversity of Utah had found that the drug TZDs act...iferator-activated receptor gamma (PPAR). This is ...e kidney. The activation of the receptor serves to...
...se like SARS, Ebola, Marburg and Avian influenza c...into from a global perspective. In an article in t...ion Society of US have suggested that instead of t...int of individual countries that are being affecte...
Other Medicine News:
(Date:12/4/2008)...lif., Dec. 4 Thoratec Co...vice-based mechanical circulatory support,therapi...id today that a,pre-specified interim analysis of...DT) pivotal trial shows that patients implanted wi...comes versus those in the control group who,were ...
(Date:12/4/2008)...e TLR8 Agonist to Advance to Clinical Trials , ...armaceuticals, Inc., a biopharmaceutical company f...tor 8 (TLR8) agonists for the treatment of cancer,...day that it has initiated a Phase I clinical trial...atment of cancer. The multi-center clinical trial...
(Date:12/3/2008)...t-line data demonstrating potential in newly diagn...emia to be featured in two oral sessions at ASH ,...for chronically transfused patients by significant..., , - New long-term data from major indepen...imal post-surgery treatment strategy, Femara vs. t...
(Date:12/3/2008)...reatment alleviates long-term anemia and organ dam...ns , , MEMPHIS, Tenn., Dec. 3 /PRNewswire-...corrective gene into mouse blood cells, scientists...eviated sickle cell disease pathology. In their st... showed essentially no difference from normal mice...
Breaking Medicine Technology:Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 2Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 3Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 4VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3Just in Time for Winter a New Berry Thats Good for Your Health 3302 1Just in Time for Winter a New Berry Thats Good for Your Health 3302 2Just in Time for Winter a New Berry Thats Good for Your Health 3302 3Novel Mass Spectrometry based Assay Reveals Degradation and Low Levels of Bioactive B type Natriuretic Peptide 28BNP 29 in Patients with Heart Failur 8323 1Novel Mass Spectrometry based Assay Reveals Degradation and Low Levels of Bioactive B type Natriuretic Peptide 28BNP 29 in Patients with Heart Failur 8323 2China Biologic Products Enters Into Agreement to Acquire 35 25 Interest in Xian Huitian Blood Products Co Ltd and Introduces Preliminary Guidance f 8318 1China Biologic Products Enters Into Agreement to Acquire 35 25 Interest in Xian Huitian Blood Products Co Ltd and Introduces Preliminary Guidance f 8318 2China Biologic Products Enters Into Agreement to Acquire 35 25 Interest in Xian Huitian Blood Products Co Ltd and Introduces Preliminary Guidance f 8318 3China Biologic Products Enters Into Agreement to Acquire 35 25 Interest in Xian Huitian Blood Products Co Ltd and Introduces Preliminary Guidance f 8318 4China Biologic Products Enters Into Agreement to Acquire 35 25 Interest in Xian Huitian Blood Products Co Ltd and Introduces Preliminary Guidance f 8318 5PAREXEL Consulting Quantifies Speed to Market 3A First Cycle Approval for NME Produces 24640 Million in Incremental Revenue on Average 8313 1PAREXEL Consulting Quantifies Speed to Market 3A First Cycle Approval for NME Produces 24640 Million in Incremental Revenue on Average 8313 2PAREXEL Consulting Quantifies Speed to Market 3A First Cycle Approval for NME Produces 24640 Million in Incremental Revenue on Average 8313 3PAREXEL Consulting Quantifies Speed to Market 3A First Cycle Approval for NME Produces 24640 Million in Incremental Revenue on Average 8313 4PAREXEL Consulting Quantifies Speed to Market 3A First Cycle Approval for NME Produces 24640 Million in Incremental Revenue on Average 8313 5
... build-up of calcium,plaque in the arteries means ...rt disease in multiple ethnic groups, according to...osclerosis (MESA),funded by the National Heart, Lu... of Health. Previous studies have shown that,incre...risk of,heart disease events and deaths in Caucasi...
...roved Outcomes in Carotid,Artery Stenting, ABBOTT ...--,Positive 30-day results from two Abbott studies...th positive results by,physicians with a variety o...l trial) settings in patients who are not favorabl... first 1,500,patients enrolled in EXACT (Emboshiel...
Other Medicine Technology:Calcium Plaque Build-up in the Arteries Leads to Coronary Heart,Disease in Multi-Ethnic Groups 2Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 2Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 3Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 4
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human
... Aerosol Resistant Tips offer a safe alternative t...are designed for applications such as PCR(a), pipe...n addition, ART Tips are excellent for tissue cult...studies. ART Tips prevent aerosol contaminants and...
...ntGard Low Binding 0.5l - 10l Eppendorf Barrier Ti...ng technology that significantly reduces the amoun... filter tips are advertised as low retention, whic... pipet tip. However, AvantGard also focuses on low...
10 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 5 & 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates.
Medicine Products: